Liquid biopsy, a noninvasive technique to obtain tumor information from body fluids, is an
emerging technology for cancer diagnosis, prognosis, and monitoring, providing crucial …

There is a high clinical unmet need to improve outcomes for pancreatic ductal
adenocarcinoma (PDAC) patients, either with the discovery of new therapies or biomarkers …

Pancreatic ductal adenocarcinoma is one of the most lethal malignant diseases, with a
mortality rate being close to incidence. Due to its heterogeneity and plasticity, as well as the …

Accumulating evidence indicates that cancer cells spread much earlier than was previously
believed. Recent technological advances have greatly improved the detection methods of …

Objective: We evaluated the prognostic impact of circulating tumor cells (CTCs) for patients
with presumed resectable pancreatic and periampullary cancers. Summary of Background …

Introduction: Pancreatic ductal adenocarcinoma (PDAC) is a disease of high lethality.
Invasive tissue biopsies of primary or metastatic lesions remain the gold standard for …

Simple Summary Metastasis is the primary cause of cancer-related deaths, but is poorly
understood. Circulating tumor cells (CTCs) seed distant sites are a promising model system …

Patients with pancreatic ductal adenocarcinoma (PDAC) are frequently staged as
unresectable locally advanced pancreatic cancer (LAPC) at the time of diagnosis. Recently …

Simple Summary Epigenetic alterations contribute to the distinct biology of pancreatic ductal
adenocarcinoma (PDAC) and thus allow a better understanding of molecular mechanisms …

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease even in the early stages,
despite progresses in surgical and pharmacological treatment in recent years. High potential …